CJC-1295 research guide for Acatipa. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Acatipa looking to source CJC-1295, the first thing to know is that this compound moves through online research channels. What this means for Acatipa researchers is that geography is secondary to your ability to evaluate vendor quality — and those evaluation tools are within reach of all serious researchers. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. This guide walks Acatipa researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Acatipa researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor share complete COA data without being asked? Vendors who do are signalling genuine quality commitment. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are below the threshold for research use. Positive vendor signals beyond COA quality: established track record of at least two years, customer service that can discuss analytical methods, and shipping with desiccant and appropriate cold protection. For Acatipa researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, order conservatively at first, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Acatipa
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is provided for educational purposes. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; do not freeze and thaw reconstituted CJC-1295 multiple times by aliquoting into single-use portions. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results reported in endotoxin units per mg or mL and verify they are within the acceptable range for your research context. The research literature on CJC-1295 should be reviewed carefully before beginning any research — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
